Simvastatin and Amiodarone: Emergence of a Potentially Toxic Interaction-Reference-Cited by-同舟云学术

Simvastatin and Amiodarone: Emergence of a Potentially Toxic Interaction

Published:2009-03 Issue:3 Volume:44 Page:221-225
ISSN:0018-5787
Container-title:Hospital Pharmacy
language:en
Short-container-title:Hosp Pharm

Author:

Backes James M.¹,Howard Patricia A.²

Affiliation:

1. Department of Pharmacy Practice; Lipid, Atherosclerosis and LDL Apheresis Center, University of Kansas Medical Center;

2. Department of Pharmacy Practice, University of Kansas Medical Center, Kansas City, Kansas.

Abstract

This continuing feature updates readers on recent developments in cardiovascular pharmacotherapy. Cardiovascular disease remains the number 1 killer in the United States, and more clinical outcome trials have been conducted in cardiology than in any other field of medicine. Given this rapidly expanding knowledge base, if pharmacists stay current with developments in drug therapy, they can have a significant impact on prevention and treatment.

Publisher

SAGE Publications

Subject

Pharmacology (medical),Pharmacology,Pharmacy

Link

http://journals.sagepub.com/doi/pdf/10.1310/hpj4403-221

Reference30 articles.

1. Prescribing Amiodarone

2. ACC/AHA/NHLBI clinical advisory on the use and safety of statins11When citing this document, the American College of Cardiology, American Heart Association, and National Heart, Lung and Blood Institute would appreciate the following citation format: Pasternak RC, Smith SC, Jr., Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C. ACC/AHA/NHLBI Advisory on the Use and Safety of Statins. J Am Coll Cardiol 2002;40:568–73.22This document is available on the Web sites of the ACC (www.acc.org), the AHA (www.americanheart.org), and the NHLBI (www.nhlbi.nih.gov/guidelines/cholesterol).

3. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial